A bi-institutional phase II study of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin (GemOx) for unresectable intrahepatic cholangiocarcinoma (ICC) Meeting Abstract
| Authors: | Cercek, A.; Kemeny, N. E.; Boerner, T.; Tan, B. R.; Chou, J. F.; Gonen, M.; Boucher, T. M.; Hauser, H.; Do, R. K. G.; Lowery, M. A.; Kingham, P.; D'Angelica, M. I.; Drebin, J. A.; Allen, P. J.; Vachharajani, N.; Doyle, M. M.; Fields, R.; Hawkins, W. G.; Chapman, W. C.; Jarnagin, W. R. |
| Abstract Title: | A bi-institutional phase II study of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin (GemOx) for unresectable intrahepatic cholangiocarcinoma (ICC) |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 224s |
| Language: | English |
| ACCESSION: | WOS:000442916001668 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.4092 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4092 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
